Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Hema Medical (03309.HK) by 10,000 shares on January 8, with a total net reduction of 390,000 shares over the past five trading days and 1,546,000 shares over the past 20 trading days [1] - As of now, southbound funds hold 75,161,000 shares of Hema Medical, which accounts for 6.09% of the company's total issued ordinary shares [1] Group 2 - Hema Medical Holdings Limited, formerly known as Hema Eye Medical Holdings Limited, is primarily engaged in providing medical services through four business segments [2] - The Hong Kong medical business segment focuses on offering ophthalmology, dentistry, and other medical services, as well as selling vision aids [2] - The mainland dental business segment is dedicated to providing dental services in mainland China [2] - The medical consumables sales segment primarily involves selling medical consumables in Hong Kong [2] - The mainland ophthalmology business segment focuses on providing ophthalmology services and selling vision aids in mainland China [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Meisi Health (02138.HK) by 39,000 shares on January 8, indicating a trend of net selling over recent trading days [1] - Over the past five trading days, southbound funds have reduced their holdings for five consecutive days, totaling a net reduction of 483,000 shares [1] - In the last twenty trading days, there has been a consistent reduction in holdings by southbound funds, with a cumulative net reduction of 1,185,000 shares [1] Group 2 - As of now, southbound funds hold 19.4 million shares of Meisi Health (02138.HK), which represents 1.7% of the company's total issued ordinary shares [1] - Meisi Health operates primarily as an investment holding company providing medical and healthcare services through three business segments [1] - The medical services segment offers medical and dental services, while the aesthetic medical, beauty, and wellness services segment provides aesthetic medical, traditional beauty, hair care, and wellness services, along with the sale of skincare, health, and beauty products [1]

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Group 1: Shareholding Changes - On November 6, southbound funds reduced their holdings by 58,000 shares, marking a decrease of 0.07% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,252,000 shares, with reductions occurring on all five days [1][2]. - In the last twenty trading days, the total net reduction reached 3,934,000 shares, with reductions on all twenty days [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 77,831,000 shares of Hema Medical, which represents 6.19% of the company's total issued ordinary shares [1][2]. Group 3: Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: Hong Kong medical services, mainland dental services, medical consumables sales, and mainland ophthalmic services [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 22, southbound funds reduced their holdings by 72,000 shares, marking a decrease of 0.09% [2]. - Over the past five trading days, there has been a cumulative net reduction of 634,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,286,000 shares, with reductions on all 20 days [1]. Current Holdings - As of the latest data, southbound funds hold a total of 79,449,000 shares of Hema Medical, which represents 6.32% of the company's total issued ordinary shares [1][2]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, as well as the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables division sells medical consumables in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - Southbound funds have significantly reduced their holdings in Hema Medical (03309.HK), indicating a bearish sentiment towards the company in recent trading days [1]. Summary by Sections Southbound Fund Holdings - On October 15, southbound funds reduced their holdings by 88,000 shares, marking a decrease of 0.11% [2]. - Over the past five trading days, there has been a cumulative net reduction of 1,242,000 shares, with reductions occurring on all five days [1][2]. - In the last 20 trading days, the total net reduction reached 3,440,000 shares, with reductions on all 20 days [1]. Current Holdings - As of now, southbound funds hold 80,083,000 shares of Hema Medical, which represents 6.37% of the company's total issued ordinary shares [1]. Company Overview - Hema Medical Holdings Limited primarily engages in providing medical services through four divisions: - The Hong Kong medical division focuses on ophthalmology, dentistry, and other medical services, along with the sale of vision aids [2]. - The mainland dental division provides dental services in mainland China [2]. - The medical consumables sales division operates in Hong Kong [2]. - The mainland ophthalmology division offers ophthalmic services and sells vision aids in mainland China [2].

Core Viewpoint - 盈健医疗 (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to shareholders was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in revenue from general medical services, specialized medical services, and dental services [1] - The gross profit also increased, attributed to the overall revenue growth [1]

Core Viewpoint - 盈健医疗 (01419.HK) reported a revenue of approximately HKD 644 million for the fiscal year 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year increase of about 8.9% [1] - The board proposed a final dividend of HKD 0.03 per share for the fiscal year 2025, up from HKD 0.028 in fiscal year 2024 [1] Revenue and Profit Growth - The company achieved a steady revenue growth despite ongoing adverse economic conditions in Hong Kong, with a revenue increase of approximately 9.1% compared to fiscal year 2024 [1] - The profit attributable to the owners increased by about 8.9% year-on-year, indicating strong financial performance [1] Business Segment Performance - The core business segments maintained balanced growth, with the primary care division showing stable performance driven by network expansion and a strong patient base [1] - The specialty medical division experienced robust revenue growth due to service upgrades and the addition of more specialists, particularly in ophthalmology, pediatric surgery, cardiology, psychiatry, and orthopedics [1] - Despite competitive pressures in the dental segment, overall revenue growth was achieved following the acquisition of Youde Dental in fiscal year 2025 [1]

Core Viewpoint - Yingjian Medical (01419) reported a revenue of approximately HKD 644.4 million for the year ending June 30, 2025, reflecting a year-on-year increase of about 9.1% [1] - The profit attributable to the company's owners was approximately HKD 26.3 million, representing a year-on-year growth of about 8.9% [1] - Basic earnings per share were approximately HKD 0.069, with a final dividend of HKD 0.03 [1] Revenue Growth - The increase in profit was primarily driven by growth in general medical services, specialized medical services, and dental services [1] - Gross profit increased due to the rise in revenue [1]

Core Viewpoint - Modern Dental Group reported a revenue of HKD 1.835 billion for the six months ending June 30, 2025, representing a year-on-year increase of 7.81% [1] - The profit attributable to the company's owners was HKD 285 million, a significant year-on-year increase of 32.52% [1] - The company plans to distribute an interim dividend of HKD 0.107 per share [1] Revenue Growth Drivers - The revenue growth was primarily driven by sustained organic growth in Europe and Australia [1] - The completion of the acquisition of Thailand's largest dental laboratory, Hexa Ceram Company Limited, in January 2025 accelerated the group's growth [1]

Core Viewpoint - Hema Medical (03309) reported a revenue increase of 2.4% year-on-year, driven by rising demand for ophthalmic medical services in Hong Kong, despite competitive pressures in Shenzhen affecting dental and ophthalmic service revenues [1] Financial Performance - Revenue for the first half of 2025 reached HKD 944 million, reflecting a year-on-year growth of 2.4% [1] - Profit attributable to equity holders amounted to HKD 49.94 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The growth in revenue was primarily attributed to increased demand for ophthalmic services in the Hong Kong market, which was partially offset by decreased revenues in Shenzhen due to intense competition in dental and ophthalmic services [1] Acquisition Announcement - Hema Medical announced the acquisition of 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]